Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Gemcitabine plus nub-paclitaxel (GEMABR) regimen was recently presented at an international
oncology meeting and represents a new standard regimen in the treatment of metastatic
pancreatic cancer. Therefore, it was decided to consider the balance of safety and efficacy
as a preoperative chemotherapy, the investigators use the NAC-GEMABR regimen includes only
two cycles (three times weekly and one week rest) of GEMABR regimen.